| Cardiovascular Function and Risk Factors | Lifetime | 44 | US 34 | 99.91 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 31 | US 10 | 99.67 |
| Heart Failure Treatment and Management | Lifetime | 44 | US 28 | 99.82 |
| Cardiac pacing and defibrillation studies | Lifetime | 171 | US 96 | 99.40 |
| Diabetes Treatment and Management | Lifetime | 172 | US 78 | 99.28 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 75 | US 45 | 98.80 |
| Cardiac Imaging and Diagnostics | Lifetime | 461 | US 241 | 99.24 |
| Cardiac Valve Diseases and Treatments | Lifetime | 539 | US 277 | 98.92 |
| Cardiovascular Disease and Adiposity | Lifetime | 438 | US 220 | 97.79 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 901 | US 348 | 97.97 |
| Parathyroid Disorders and Treatments | Lifetime | 667 | US 273 | 96.28 |
| Systemic Sclerosis and Related Diseases | Lifetime | 664 | US 207 | 95.67 |
| Cardiovascular Issues in Pregnancy | Lifetime | 710 | US 304 | 95.09 |
| Cardiac Fibrosis and Remodeling | Lifetime | 822 | US 293 | 90.98 |
| Potassium and Related Disorders | Lifetime | 524 | US 255 | 91.11 |
| Phonocardiography and Auscultation Techniques | Lifetime | 601 | US 167 | 84.61 |
| Heart rate and cardiovascular health | Lifetime | 425 | US 127 | 78.51 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 9 | US 7 | 99.96 |
| Heart Failure Treatment and Management | 2021-2025 | 17 | US 11 | 99.87 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 28 | US 13 | 99.57 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 30 | US 9 | 98.91 |
| Diabetes Treatment and Management | 2021-2025 | 65 | US 35 | 99.29 |
| Parathyroid Disorders and Treatments | 2021-2025 | 29 | US 10 | 98.35 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 29 | US 13 | 98.72 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 276 | US 90 | 97.95 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 316 | US 85 | 97.84 |
| Cardiovascular Effects of Exercise | 2021-2025 | 187 | US 60 | 95.08 |
| Cardiovascular and exercise physiology | 2021-2025 | 255 | US 50 | 94.81 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 631 | US 174 | 95.15 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 790 | US 287 | 95.18 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 248 | US 67 | 92.63 |
| Peptidase Inhibition and Analysis | 2021-2025 | 448 | US 119 | 92.06 |
| Pancreatic function and diabetes | 2021-2025 | 489 | US 174 | 92.26 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 727 | US 188 | 88.83 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 548 | US 133 | 86.65 |
| Hormonal Regulation and Hypertension | 2021-2025 | 417 | US 103 | 87.99 |
| Potassium and Related Disorders | 2021-2025 | 132 | US 55 | 89.15 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 744 | US 175 | 66.08 |
| Heart rate and cardiovascular health | 2021-2025 | 87 | US 21 | 64.05 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 398 | US 64 | 61.35 |
| Electrolyte and hormonal disorders | 2021-2025 | 985 | US 240 | 58.69 |
